Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported fourth‑quarter 2025 results that saw total revenue rise 25% to $207 million, surpassing the consensus estimate of roughly $200 million. The company posted a net loss of $129 million, translating to earnings per share of $‑1.29. While revenue beat expectations, the loss widened relative to the consensus EPS estimate of about $‑1.15 to $‑1.20, indicating that higher operating expenses and a one‑time restructuring charge outweighed the upside from sales growth.
The quarter’s revenue growth reflects a 20% year‑over‑year increase in full‑year 2025 revenue, which reached $673 million compared with $564 million in 2024. The company’s net loss of $129 million represents a larger decline than the $575 million loss reported for the full year, underscoring the ongoing challenge of translating sales momentum into profitability.
Management announced a 10% workforce reduction, cutting roughly 130 employees, as part of a broader restructuring plan aimed at reducing operating expenses. The plan includes a 38% cut in research and development spending and a 15% reduction in SG&A, designed to align resources with the company’s highest‑impact opportunities and to set a path toward profitability by 2027.
Ultragenyx guided 2026 revenue to $730–$760 million, a range that falls short of analyst expectations of about $785 million to $803 million. Investors reacted to the guidance shortfall and the EPS miss, which tempered enthusiasm for the company’s outlook despite the revenue beat.
The company continues to face regulatory headwinds, with the FDA requesting additional documentation for its gene‑therapy candidate UX111 and two late‑stage trials for setrusumab failing to meet primary endpoints. Nevertheless, strong sales from Crysvita, Dojolvi, and Evkeeza have driven the revenue growth, and management remains optimistic about future product launches and data readouts that could accelerate commercial momentum.
CEO Emil D. Kakkis said, “The year ahead marks an important turning point for the company, as we approach two potential product launches and a pivotal data readout that, together, could significantly accelerate our commercial revenue trajectory.” He added, “We are implementing a strategic restructuring plan to reduce our operating expenses and ensure our resources are squarely aligned with our highest‑impact opportunities, while leading the future of rare disease with multiple first‑ever treatments.” CFO Howard Horn noted, “Ultragenyx reported 2025 total revenue of $673 million, up 20% from 2024 and above the upper end of the company’s guidance range.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.